A multicentre randomised study on percutaneous stellate ganglion block as first line treatment in patients with electrical storm: the STAR 2 study

Status

Withdrawn

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-520387-34-00

Acronym

STAR 2

Enrollment

180

Registered

2025-11-25

Start date

Unknown

Completion date

Unknown

Last updated

2025-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

electrical storm

Brief summary

proportion of patients with complete suppression of treated VA (with ATP, internal DC shock or external DC shock) during the first three hours after treatment

Interventions

DRUGAmiodarone Hikma 50 mg/ml soluzione iniettabile

DRUGBUPISEN 5 mg/ml soluzione iniettabile

DRUGLidocaina Kabi 20 mg/ml soluzione iniettabile

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
proportion of patients with complete suppression of treated VA (with ATP, internal DC shock or external DC shock) during the first three hours after treatment	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026